Dr RR Baliga's "Got Knowledge Doc" Podkast

⚡🫀 Shock. Silence. Success — A landmark New England Journal of Medicine trial redefines first-line therapy in persistent AF.   In AVANT GUARD, pulsed field ablation (PFA) outperformed antiarrhythmic drugs: 📊 Success: 56% vs 30% 📉 HR: 0.46 (P

A fascinating Science (2026) study reveals why the heart is remarkably resistant to cancer. Mechanical load—through contraction and pressure—suppresses tumor proliferation via epigenetic remodeling.  Unloading the heart doubled cancer cell proliferation, while load reduced histone methylation and chromatin compaction through Nesprin-2–mediated mechanotransduction. A striking paradigm: the beating...

A simple idea, executed elegantly.   In the NEJM TRIDENT trial , a single low-dose triple antihypertensive pill reduced recurrent stroke after intracerebral hemorrhage (HR 0.61) and improved BP control (50% vs 26%).   Yet, only half reached target—reminding us that pills alone don't solve therapeutic inertia.   The message is clear: simplify treatment, intensify targets, and build systems that ens...

A pivotal JAMA randomized trial introduces an epigenetic twist to frontline therapy in high-risk DLBCL. Adding tucidinostat (HDAC inhibitor) to R-CHOP improved event-free survival (HR 0.72, P=0.02) and increased complete response rates (73% vs 62%) in MYC/BCL2 double-expressor lymphoma. Toxicity was higher but manageable.   A quiet but meaningful shift—targeting biology, not just burden.   #DLBCL...

A pragmatic Lancet RCT (SCOUT) reshapes UTI management. In 768 women, nitrofurantoin achieved the highest clinical resolution at day 7 (74%) vs single-dose fosfomycin (59%), with a significant 15.5% absolute difference. Pivmecillinam and two-dose fosfomycin performed intermediately. Adverse events were mild across groups.   The message is clear: convenience may cost efficacy. Short-course regimens...

A large nationwide cohort study in JAMA compared amoxicillin-clavulanate vs amoxicillin for acute sinusitis in >500,000 adults. Treatment failure was low (~3%) with no significant difference between groups (RR 0.96). However, broader-spectrum therapy increased secondary infections, including yeast and C. difficile .   The message is clear: narrow-spectrum amoxicillin remains a rational first-line...

A quiet revolution in medicine began not in a laboratory—but in a dialogue. 🌿   Punarvasu Atreya, one of the earliest architects of Ayurveda, transformed healing into a disciplined science through teaching, inquiry, and debate. His legacy—preserved in the Charaka Samhita and Bhela Samhita —shaped centuries of clinical reasoning and holistic care.   From Takshashila to modern medicine, his influen...

A thoughtful, practice-shaping study in NEJM explores a long-standing clinical dilemma: can we truly move the needle in post-thrombotic syndrome?   The C-TRACT trial shows that endovascular therapy (iliac-vein stenting) significantly improves symptom burden and quality of life in patients with moderate–severe disease—measured rigorously using VCSS, VEINES-QOL, and SF-36. The magnitude of benefit i...

A landmark study in the New England Journal of Medicine shows that hypertension control is no longer just about prescribing medications—it's about systems, teams, and sustained engagement . 🩺📊   In a cluster-randomized trial across underserved populations, a multifaceted, team-based strategy —combining protocol-driven care, health coaching, and home BP monitoring—achieved a significant additiona...

Sex hormones shape cardiovascular risk in subtle yet powerful ways. From estrogen-driven changes in coagulation to formulation-specific differences in VTE risk, the nuance matters. Transdermal estradiol offers a safer path, while ethinyl estradiol reminds us that dose and route are destiny. The key is not avoidance—but precision: matching therapy to individual risk.   Three takeaways: • Formulatio...

  A landmark JAMA study on transcatheter tricuspid valve replacement (TTVR) offers compelling real-world evidence 🫀   ✅ 98.4% procedural success ✅ Near-complete TR elimination (97.7% at 30 days) ✅ Significant improvement in symptoms & quality of life ⚠️ Trade-off: ~16% new pacemaker rate in device-naïve patients   In an elderly, high-risk cohort, TTVR delivers what surgery often cannot— restor...

  A quiet shift, yet a profound one. 🧠   The OCEANIC-STROKE trial introduces asundexian , a Factor XIa inhibitor that lowers recurrent ischemic stroke risk (HR 0.74) without increasing major bleeding—a long-sought balance in antithrombotic therapy.   For decades, we traded efficacy for safety. Now, we may finally have both. ⚖️   The implications extend beyond stroke—to a broader rethinking of thr...

  🧠 Brain metastases remain a clinical frontier—common, complex, and still lethal. In Science Signaling , Chafe et al. unpack the biology: Blood Brain Barrier traversal, metabolic rewiring, and immune evasion.   Key insight: metastasis is not just spread—it is adaptation.   From adenosine-driven immunosuppression to neuronal-like tumor states, new therapeutic doors are opening.   Precision oncolo...

What if the roots of modern surgery were written over 2,000 years ago? 🩺📜   Meet Suśruta —a pioneer whose Suśruta Saṃhitā laid the foundations of plastic surgery, cataract procedures, and structured medical training. From rhinoplasty to hands-on simulation using natural models, his approach was remarkably ahead of its time.   A reminder that innovation is often rediscovery—and that the future of...

  🧠💊 Stop. Test. Rethink.   A compelling new study in JAMA shows that ~26% of adults ≥60 years can safely discontinue levothyroxine , maintaining normal thyroid function—especially those on low doses (≤50 μg/day) .   📉 No meaningful decline in quality of life 📊 Clear dose-response signal ⚠️ Raises concerns about lifelong overtreatment   The message is elegant: Not every prescription deserves p...

A fascinating step forward in Nature —where immunology meets cardiology. 🧬❤️   This study shows that engineered dendritic cells can locally reprogram the immune response , reduce fibrosis, and improve cardiac function—without systemic immunosuppression.   The insight is simple, yet profound: 👉 Heart failure is not just hemodynamic—it is immunologic.   From FAP-targeted delivery to checkpoint-med...

🧠⏳ Age. Biology. Truth.   A compelling Perspective in the New England Journal of Medicine challenges one of medicine's quiet assumptions: that age equals risk.   Two patients may share a birth year—but not a biology. From epigenetic clocks to physiological reserve, the evidence is clear: chronologic age is an imperfect proxy for clinical decision-making     ⚠️ The consequence? Missed prevention...

Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉   A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects.   📊 Signal: modest for weight loss, stronger for tolerability 🧠 Insight: genetics + clinical factors explain ~25% variability 🚀 Implication: early steps toward precisio...

Master athletes challenge one of medicine's most elegant assumptions: that fitness always protects.   In the Journal of the American College of Cardiology (JACC) consensus statement on athletes with abnormal cardiovascular findings, a paradox emerges—higher fitness, yet distinct patterns of risk: atrial fibrillation, coronary calcium, myocardial fibrosis.   The lesson is not to discourage exercise...

A compelling study in PLOS Medicine : sustained moderate-to-vigorous physical activity across midlife is associated with a ~50% reduction in all-cause mortality in women (target trial emulation). Not intensity, not intermittence— consistency is the signal . For clinicians, the prescription is enduring: move often, move steadily, move for life. 🏃‍♀️💓   #PLOSMedicine #PreventiveCardiology #Lifesty...

The origins of medicine are not merely scientific—they are deeply philosophical. In our Great Doctors Series , we begin with Dhanvantari, the divine physician of Ayurveda, emerging from myth into method. From the Ocean of Milk to the clinics of today, this episode explores how healing began as a sacred science. For students and physicians alike, it is a reminder that medicine is not just practiced...

A fascinating and somewhat unsettling observation from JACC: Asia : nearly 1 in 4 STEMI patients in New Delhi had no traditional risk factors —no hypertension, diabetes, dyslipidemia, or smoking. Yet outcomes tell a different story. Despite fewer signs of heart failure at presentation, these patients had worse left ventricular dysfunction and identical in-hospital and 1-year mortality compared wit...

A thoughtful and important JACC State-of-the-Art Review reframes cardiogenic shock not as a single ICU event, but as a longitudinal survivorship journey. The article highlights recovery, remission, native heart survival, PICS, HF GDMT optimization, and the need for structured multidisciplinary postshock clinics focused on function, cognition, quality of life, and recurrent risk after discharge. A...

A landmark 10-year follow-up of the HOST-EXAM trial published in The Lancet challenges a century-old assumption: aspirin may no longer be the default for lifelong secondary prevention after PCI.   Clopidogrel demonstrated a sustained reduction in ischemic and bleeding events (HR 0.86, p=0.005), with benefits that accumulated over time—yet without a mortality difference.   The implication is subtle...

🫀 In the New England Journal of Medicine, the SMART-DECISION trial asks a practical modern question: after myocardial infarction, should stable patients without heart failure or marked left ventricular systolic dysfunction remain on beta-blockers indefinitely? In this randomized noninferiority trial, stopping beta-blockers after at least 1 year was noninferior to continuing them for the composite...